SCHEMBL4548624

SCHEMBL4548624

CC(C)(C)c1ccc2cc(C(C)(C)C)nnc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.37
▸ SCN10A Q9Y5Y9 4/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ HRH4 Q9H3N8 2/20 0.33
▸ HRH3 Q9Y5N1 2/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ FBP1 P09467 1/20 0.32
▸ METAP2 P50579 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21451306 0.87 BACE1 (0.41) SCN10AKCNH2ALDH1A1LRRK2HPGD
SCHEMBL14427134 0.77 TERT (0.46) TSHRSCN10AKCNH2ALDH1A1HPGD
SCHEMBL2707037 0.76 TSHR (0.39) TSHRSCN10AKCNH2ALDH1A1HPGD
SCHEMBL9928483 0.76 KDM4E (0.50) ALDH1A1HPGDTDP1MEN1KMT2A
SCHEMBL2704185 0.74 KCNH2 (0.42) TSHRSCN10AKCNH2ALDH1A1LRRK2
SCHEMBL25782693 0.73 SCN10A (0.37) TSHRSCN10AKCNH2ALDH1A1LRRK2
SCHEMBL13438759 0.73 SCN10A (0.37) TSHRSCN10AKCNH2ALDH1A1LRRK2
SCHEMBL21451305 0.72 BACE1 (0.37) —
SCHEMBL1695518 0.71 TRPV1 (0.40) SCN10AKCNH2ALDH1A1HPGDALOX15
SCHEMBL23118240 0.70 SCN10A (0.47) TSHRSCN10AKCNH2ALDH1A1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET TSHR 3003/4885SCN10A 4439/4885KCNH2 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback